Neurodegenerative diseases affect more than 30 million people worldwide.
There are no approved disease-modifying drugs.
Mitokinin aims to change that.

Our Approach

Validated Target: PINK1

PINK1 is a master regulator of mitochondrial quality control. Mutations in PINK1 give rise to familial forms of Parkinson’s disease. Increased PINK1 activity rescues pathologies associated with neurodegenerative disease.

Learn more about PINK1

Advanced Therapeutics

Mitokinin has advanced small molecule therapeutics that specifically increase the activity of active-form PINK1. Importantly, Mitokinin’s compounds do not interfere with the endogenous regulation of PINK1.

Learn more about our therapeutics

Winning Team

Mitokinin has an accomplished team of neuroscientists, chemists, pharmacologists, and administrative professionals all focused on our mission: delivering disease-modifying therapies for neurodegenerative disease.

Learn more about our team

Mitokinin has combined a genetically validated target, a class of potent, highly selective small molecules, and a world-class scientific team to tackle the most critical unmet medical need of our time.

Multi-Indication Opportunity

Though PINK1 is most closely associated with Parkinson’s disease, mitochondrial dysfunction is implicated in many disease of aging. Academic studies have shown that PINK1 amplification may have therapeutic benefit in Alzheimer’s disease, Huntington’s disease, pulmonary and kidney fibrosis, NASH, and more.

Learn More